It has been reported that GPR17 mediates immune response and ischemic/inflammatory states, including stroke and some neurodegenerative diseases (Zhao et al., 2018) GPR17 receptor may be a target for stroke, brain and spinal cord injury, and diseases characterized by neuronal and myelin dysfunctions (Bonfanti et al., 2017, 2020; He et al., 2018). This evidence concerns the gene GPR17 and neurodegenerative disease.